Verification evidence is still being completed.
PDF / print export
Thor Medical ASA
Oslo, Norway
- Verified lead
- Alf Bjorseth
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Alpha-Emitter Radiopharmaceuticals, Radium-224 and Pb-212 Production, Oncology Radionuclide Therapy
- Review cycle
- 24 April 2026
- Full address
- Drammensveien 167, NO-0277 Oslo, Norway
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Thor Medical / Nordic Nanovector merger agreement announcement.
- Editorial note
- Oslo-listed radiopharmaceutical developer pivoting from legacy antibody-radionuclide conjugates to alpha-emitter production, with a pilot Heroya radionuclide facility and a named CEO.
Alpha-Emitter Radiopharmaceuticals, Radium-224 and Pb-212 Production, Oncology Radionuclide Therapy
Oslo Stock Exchange listing, Norwegian company registry (org. 994 297 422), Documented merger agreement
Oslo-listed radiopharmaceutical developer pivoting from legacy antibody-radionuclide conjugates to alpha-emitter production, with a pilot Heroya radionuclide facility and a named CEO.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Oslo, Norway
Thor Medical ASA
Alpha-Emitter Radiopharmaceuticals, Radium-224 and Pb-212 Production, Oncology Radionuclide Therapy · Pilot radiopharmaceutical production
Verified 24 Apr 2026 · 2 sources
Pilot
Oslo-listed radiopharmaceutical developer pivoting from legacy antibody-radionuclide conjugates to alpha-emitter production, with a pilot Heroya radionuclide facility and a named CEO.
Contact & location
- Website
- thormedical.com
- Company page
- Lead
- Alf Bjorseth (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Pilot radiopharmaceutical production
- Capabilities
- Alpha-Emitter Radiopharmaceutical Production · Antibody-Radionuclide Conjugate IP (legacy) · Pilot Radionuclide Production at Heroya
- Founded
- 2023
- Headcount
- 11-50
Clinical profileSTATUS: VERIFIED APRIL 2026
Alf Bjorseth
Chief Executive Officer
Full addressDrammensveien 167, NO-0277 Oslo, Norway
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Norwegian company registry listing Drammensveien 167, Oslo as the registered office.
Open sourcePilot radiopharmaceutical production
Oslo, Norway. Alpha-Emitter Radiopharmaceuticals, Radium-224 and Pb-212 Production, Oncology Radionuclide Therapy. Review completed on 24 Apr 2026.
Norwegian Medicines Agency and radiation-safety authority
Oslo Stock Exchange listing, Norwegian company registry (org. 994 297 422), Documented merger agreement
Alpha-Emitter Radiopharmaceuticals, Radium-224 and Pb-212 Production, Oncology Radionuclide Therapy
Oslo-listed radiopharmaceutical developer pivoting from legacy antibody-radionuclide conjugates to alpha-emitter production, with a pilot Heroya radionuclide facility and a named CEO.
Editorial note
Thor Medical is the post-merger successor to Nordic Nanovector, pivoting from the legacy Betalutin anti-CD37 program to alpha-emitter radiopharmaceutical production; Oslo Stock Exchange listing carried over under the Thor Medical identity.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Alpha-Emitter Radiopharmaceutical Production
Antibody-Radionuclide Conjugate IP (legacy)
Pilot Radionuclide Production at Heroya
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Alpha-emitter production infrastructure
Pilot radionuclide facility at Heroya
Oslo corporate and R&D offices
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Thor Medical ASA located?
- Thor Medical ASA operates from Drammensveien 167, NO-0277 Oslo, Norway, Oslo, Norway.
- Who runs Thor Medical ASA?
- Thor Medical ASA is led by Alf Bjorseth, Chief Executive Officer. Verified 24 Apr 2026.
- What does Thor Medical ASA do?
- Oslo-listed radiopharmaceutical developer pivoting from legacy antibody-radionuclide conjugates to alpha-emitter production, with a pilot Heroya radionuclide facility and a named CEO. Core capabilities: Alpha-Emitter Radiopharmaceutical Production, Antibody-Radionuclide Conjugate IP (legacy), Pilot Radionuclide Production at Heroya.
Editorial context
Related technical briefs
Briefs that name Oslo as a covered market or city.